09:08 AM EDT, 05/30/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) initiated a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS, BriaCell's personalized off-the-shelf next generation immunotherapy, as monotherapy and in combination with a PD-1 inhibitor, tislelizumab, in advanced metastatic breast cancer.

Briacell says the off-the-shelf nature of the treatment will allow patients to be treated rapidly.

"We believe personalization through our Bria-OTS immunotherapy platform will produce more potent and long-lasting responses than previously observed, with potential synergistic effects with the immune check point inhibitor," said Dr. William Williams, BriaCell's president & CEO.